Engineered GPCRs as tools to modulate signal transduction

Physiology

Volumn 23, Issue 6, 2008, Pages 313-321

  Pei, Ying ^a   Rogan, Sarah C ^a   Yan, Feng ^a   Roth, Bryan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

ARTICLE; CHEMICAL STRUCTURE; DRUG EFFECT; GENETICS; HUMAN; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION;

HUMANS; MODELS, MOLECULAR; PROTEIN ENGINEERING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 57749114392     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00025.2008     Document Type: Article

References (56)

1. Abbas A, Roth BL. Arresting serotonin. Proc Natl Acad Sci USA 105: 831-832, 2008.
2. Ackland-Berglund CE, Leib DA. Efficacy of tetracycline-controlled gene expression is influenced by cell type. Biotechniques 18: 196-200, 1995.
3. Alves-Rodrigues A, Leurs R, Willems E, Timmerman H. Binding of clozapine metabolites and analogues to the histamine H3 receptor in rat brain cortex. Arch Pharm (Weinheim) 329: 413-416, 1996.
4. Ardizzone TD, Bradley RJ, Freeman AM 3rd, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 923: 82-90, 2001.
5. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 104: 5163-5168, 2007.
6. Birnbaumer L, Rodbell M. Adenyl cyclase in fat cells. II. Hormone receptors. J Biol Chem 244: 3477-3482, 1969.
7. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 18: 1723-1729, 1999.
8. Bruysters M, Jongejan A, Akdemir A, Bakker RA, Leurs R. A G(q/11)-coupled mutant histamine H(1) receptor F435A activated solely by synthetic ligands (RASSL). J Biol Chem 280: 34741-34746, 2005.
9. Chang WC, Ng JK, Nguyen T, Pellissier L, Claeysen S, Hsiao EC, Conklin BR. Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLoS ONE 2: e1317, 2007.
10. Claeysen S, Joubert L, Sebben M, Bockaert J, Dumuis A. A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). J Biol Chem 278: 699-702, 2003.
11. Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, Forsayeth JR, Guettier JM, Chang WC, Pei Y, McCarthy KD, Nissenson RA, Wess J, Bockaert J, Roth BL. Engineering GPCR signaling pathways with RASSLs. Nat Methods 5: 673-678, 2008.
12. Coward P, Wada HG, Falk MS, Chan SD, Meng F, Akil H, Conklin BR. Controlling signaling with a specifically designed Gi-coupled receptor. Proc Natl Acad Sci USA 95: 352-357, 1998.
13. Fu LX, Liang QM, Waagstein F, Hoebeke J, Sylven C, Jansson E, Sotonyi P, Hjalmarson A. Increase in functional activity rather than in amount of Gialpha in failing human heart with dilated cardiomyopathy. Cardiovasc Res 26: 950-955, 1992.
14. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21: 90-113, 2000.
15. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89: 5547-5551, 1992.
16. Guettier JM, Gautam D, Scarselli M, Lu H, Ma X, Gonzales F, Armbruster B, Roth BL, Wess J. In vivo control of distinct G protein pathways in pancreatic beta-cells. Islet Biology Keystone Meeting, 2008.
17. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 99: 25-44, 2003.
18. Holmer SR, Homcy CJ. G proteins in the heart. A redundant and diverse transmembrane signaling network. Circulation 84: 1891-1902, 1991.
19. Hsiao EC, Boudignon BM, Chang WC, Bencsik M, Peng J, Nguyen TD, Manalac C, Halloran BP, Conklin BR, Nissenson RA. Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. Proc Natl Acad Sci USA 105: 1209-1214, 2008.
20. Jacobson KA, Gao ZG, Liang BT. Neoceptors: reengineering GPCRs to recognize tailored ligands. Trends Pharmacol Sci 28: 111-116, 2007.
21. Josefsson LG. Evidence for kinship between diverse G-protein coupled receptors. Gene 239: 333-340, 1999.
22. Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA, Roth BL. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J Pharmacol Exp Ther 293: 735-746, 2000.
23. Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci 116: 4867-4869, 2003.
24. Li X, Gutierrez DV, Hanson MG, Han J, Mark MD, Chiel H, Hegemann P, Landmesser LT, Herlitze S. Fast noninvasive activation and inhibition of neural and network activity by vertebrate rhodopsin and green algae channelrhodopsin. Proc Natl Acad Sci USA 102: 17816-17821, 2005.
25. 2+ handling, myofilament injury, and dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 294: H205-H212, 2008.
26. Moepps B, Fagni L. Mont Sainte-Odile: a sanctuary for GPCRs. Confidence on signal transduction of G-protein-couple receptors. EMBO Rep 4: 237-243, 2003.
27. Mueller KL, Hoon MA, Erlenbach I, Chandrashekar J, Zuker CS, Ryba NJ. The receptors and coding logic for bitter taste. Nature 434: 225-229, 2005.
28. Nawaratne V, Leach K, Suratman N, Loiacono RE, Felder CC, Armbruster BN, Roth BL, Sexton PM, Christopoulos A. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol 74: 1119-1131, 2008.
29. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 93: 3346-3351, 1996.
30. Paterlini G, Portoghese PS, Ferguson DM. Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the kappa-opioid receptor. A model for receptor activation. J Med Chem 40: 3254-3262, 1997.
31. Pauwels PJ. Unravelling multiple ligand-activation binding sites using RASSL receptors. Trends Pharmacol Sci 24: 504-507, 2003.
32. Peng J, Bencsik M, Louie A, Lu W, Millard S, Nguyen P, Burghardt A, Majumdar S, Wronski TJ, Halloran B, Conklin BR, Nissenson RA. Conditional expression of a Gi-coupled receptor in osteoblasts results in trabecular osteopenia. Endocrinology 149: 1329-1337, 2008.
33. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, Conklin BR. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat Biotechnol 17: 165-169, 1999.
34. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevicz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci USA 97: 4826-4831, 2000.
35. Regard JB, Sato IT, Coughlin, SR. Anatomical profiling of G protein-coupled receptor expression. Cell 135: 561-571, 2008.
36. Roth BL. Drugs and valvular heart disease. N Engl J Med 356: 6-9, 2007.
37. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-1410, 1994.
38. Sakamoto A, Chen M, Nakamura T, Xie T, Karsenty G, Weinstein LS. Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone. J Biol Chem 280: 21369-21375, 2005.
39. Salmi P, Ahlenius S. Further evidence for clozapine as a dopamine D1 receptor agonist. Eur J Pharmacol 307: 27-31, 1996.
40. Scearce-Levie K, Coward P, Redfern CH, Conklin BR. Engineering receptors activated solely by synthetic ligands (RASSLs). Trends Pharmacol Sci 22: 414-420, 2001.
41. Scearce-Levie K, Lieberman MD, Elliott HH, Conklin BR. Engineered G protein coupled receptors reveal independent regulation of internalization, desensitization and acute signaling. BMC Biol 3: 3, 2005.
42. Scott MM, Wylie CJ, Lerch JK, Murphy R, Lobur K, Herlitze S, Jiang W, Conlon RA, Strowbridge BW, Deneris ES. A genetic approach to access serotonin neurons for in vivo and in vitro studies. Proc Natl Acad Sci USA 102: 16472-16477, 2005.
43. Small KM, Brown KM, Forbes SL, Liggett SB. Modification of the beta 2-adrenergic receptor to engineer a receptor-effector complex for gene therapy. J Biol Chem 276: 31596-31601, 2001.
44. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science 262: 1019-1024, 1993.
45. Srinivasan S, Vaisse C, Conklin BR. Engineering the melanocortin-4 receptor to control G(s) signaling in vivo. Ann NY Acad Sci 994: 225-232, 2003.
46. Strader CD, Candelore MR, Hill WS, Dixon RA, Sigal IS. A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. J Biol Chem 264: 16470-16477, 1989.
47. Strader CD, Gaffney T, Sugg EE, Candelore MR, Keys R, Patchett AA, Dixon RA. Allele-specific activation of genetically engineered receptors. J Biol Chem 266: 5-8, 1991.
48. Subramanian G, Paterlini MG, Larson DL, Portoghese PS, Ferguson DM. Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. J Med Chem 41: 4777-4789, 1998.
49. Sweger EJ, Casper KB, Scearce-Levie K, Conklin BR, McCarthy KD. Development of hydrocephalus in mice expressing the G(i)-coupled GPCR Ro1 RASSL receptor in astrocytes. J Neurosci 27: 2309-2317, 2007.
50. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13, 2007.
51. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28: 416-422, 2007.
52. Wan XH, Huang XQ, Zhou DH, Jiang HL, Chen KX, Chi ZQ. Building 3D-structural model of kappa opioid receptor and studying its interaction mechanism with dynorphin A(1-8). Acta Pharmacol Sin 21: 701-708, 2000.
53. Wang Y, O'Malley BW Jr, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 91: 8180-8184, 1994.
54. Yan F, Mosier PD, Westkaemper RB, Roth BL. Galpha-subunits differentially alter the conformation and agonist affinity of kappa-opioid receptors. Biochemistry 47: 1567-1578, 2008.
55. Yan F, Mosier PD, Westkaemper RB, Stewart J, Zjawiony JK, Vortherms TA, Sheffler DJ, Roth BL. Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors. Biochemistry 44: 8643-8651, 2005.
56. Zhao GQ, Zhang Y, Hoon MA, Chandrashekar J, Erlenbach I, Ryba NJ, Zuker CS. The receptors for mammalian sweet and umami taste. Cell 115: 255-266, 2003.